Schering-Plough launches sugammadex in first market, Sweden
This article was originally published in Scrip
Executive Summary
Schering-Ploughhas launched Bridion (sugammadex, 100mg/ml), its injectable neuromuscular blockade reversal agent, in its first market, Sweden, and further introductions are expected soon in the UK, Germany and other European markets. It has also been filed for approval in Japan.